Traws Pharma, Inc.
TRAW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 1.77 | 0.13 | 0.05 |
| FCF Yield | -216.07% | -114.00% | -119.89% | -45.40% |
| EV / EBITDA | 0.05 | 0.25 | 1.28 | 0.74 |
| Quality | ||||
| ROIC | -367.47% | -150.77% | -62.65% | -33.42% |
| Gross Margin | 94.69% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.54 | 0.95 | 0.86 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.00% | 0.00% | -0.73% | -53.04% |
| Free Cash Flow Growth | -66.01% | -10.14% | 16.39% | 15.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 1.03 | 1.98 | 3.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -246,140.28 | 29.07 | 46.84 | 45.22 |